Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Oncogenic NRAS Primes Primary Acute Myeloid Leukemia Cells for Differentiation.

PloS one - 1 Jan 2015

Brendel Cornelia, Teichler Sabine, Millahn Axel, Stiewe Thorsten, Krause Michael, Stabla Kathleen, Ross Petra, Huynh Minh, Illmer Thomas, Mernberger Marco, Barckhausen Christina, Neubauer Andreas

Abstract excerpt

RAS mutations are frequently found among acute myeloid leukemia patients (AML), generating a constitutively active signaling protein changing cellular proliferation, differentiation and apoptosis. We have previously shown that treatment of AML patients with high-dose cytarabine is preferentially...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cytarabine
Share to GTP Phosphohydrolases
Share to Leukemia, Myeloid, Acute

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Myeloid Cells

Share to Myeloid Ecotropic Viral Integration Site 1 Protein

Share to Neoplasm Proteins

Share to Oncogene Proteins, Fusion

Share to ras Proteins

Source

Open in PubMed Open full text

Identifiers

PMID: 25901794
DOI: 10.1371/journal.pone.0123181
PMCID: PMC4406710

Genes

NRAS
MEIS1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026. Prepared record publication-25901794-2026-09-04.2. Manifest publication-graph-cohort-2026-09-04.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Oncogenic NRAS Primes Primary Acute Myeloid Leukemia Cells for Differentiation.PMID 25901794Read ↗

RAS oncogene suppression induces apoptosis followed by more differentiated and less myelosuppressive disease upon relapse of acute myeloid leukemiaSemantic proximity Read ↗

Distinct gene expression patterns associated with FLT3- and NRAS-activating mutations in acute myeloid leukemia with normal karyotype.Semantic proximity Read ↗

Oncogenic RAS enables DNA damage- and p53-dependent differentiation of acute myeloid leukemia cells in response to chemotherapy.Semantic proximity Read ↗

Preclinical efficacy of MEK inhibition in Nras-mutant AML.Semantic proximity Read ↗

p53-/- synergizes with enhanced NrasG12D signaling to transform megakaryocyte-erythroid progenitors in acute myeloid leukemia.Semantic proximity Read ↗

NRAS G12V oncogene facilitates self-renewal in a murine model of acute myelogenous leukemiaSemantic proximity Read ↗

[NRAS Gene Expression and Its Clinical Significance in Patients with Acute Myeloid Leukemia].Semantic proximity Read ↗

Early changes in gene expression profiles in AML patients during induction chemotherapySemantic proximity Read ↗

Oncogenic NRAS rapidly and efficiently induces CMML- and AML-like diseases in mice.Semantic proximity Read ↗

NRAS mutations in de novo acute leukemia: prevalence and clinical significance.Semantic proximity Read ↗

PRAME-Induced Inhibition of Retinoic Acid Receptor Signaling-Mediated Differentiation—A Possible Target for ATRA Response in AML without t(15;17)Semantic proximity Read ↗

Nras(G12D/+) promotes leukemogenesis by aberrantly regulating hematopoietic stem cell functions.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.